FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cidara Therapeutics's Free Cash Flow for the
three
months ended in Dec. 2023 was $-12.90 Mil. Cidara Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $17.58 Mil. Therefore, Cidara Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -73.37%.
As of today, Cidara Therapeutics's current FCF Yield % is -40.93%.
The historical rank and industry rank for Cidara Therapeutics's FCF Margin % or its related term are showing as below:
CDTX'
s FCF Margin % Range Over the Past 10 Years
Min: -452.45 Med: -50.98 Max: -35.89
Current: -35.89
During the past 11 years, the highest FCF Margin % of Cidara Therapeutics was -35.89%. The lowest was -452.45%. And the median was -50.98%.
CDTX's FCF Margin % is ranked better than 64.89% of 1031
companies
in the Biotechnology industry
Industry Median: -148.24
vs CDTX: -35.89
Cidara Therapeutics FCF Margin % Historical Data
The historical data trend for Cidara Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cidara Therapeutics's FCF Margin %
For the Biotechnology subindustry, Cidara Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cidara Therapeutics's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cidara Therapeutics's FCF Margin % falls into.
Cidara Therapeutics FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Cidara Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cidara Therapeutics FCF Margin % Related Terms
Thank you for viewing the detailed overview of Cidara Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cidara Therapeutics (Cidara Therapeutics) Business Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDTX has been successfully added to your 